Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hullo! Turns out Jay Bradner is moving from academia and Novartis to serve as Amgen’s new CSO. Also, the FDA has a new registry of trial sponsors and investigators who didn’t finish their paperwork. Have a nice weekend!
Is no one safe from the FTC?
Has Pfizer bottomed out? And is biotech finally back? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect